Thomas Bahmer

Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial

Jürgen Behr, Antje Prasse, Michael Kreuter et al. · The Lancet Respiratory Medicine · 2021 · 516 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +9

Longitudinal Multi-omics Analyses Identify Responses of Megakaryocytes, Erythroid Cells, and Plasmablasts as Hallmarks of Severe COVID-19

Joana P. Bernardes, Neha Mishra, Florian Tran et al. · Immunity · 2020 · 407 citations · Full text

Life Sciences, Cell Biology, Hematology +16

Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry

Jürgen Behr, Michael Kreuter, Marius M. Hoeper et al. · European Respiratory Journal · 2015 · 244 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +17

Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry

Michael Kreuter, Jeff Swigris, David Pittrow et al. · Respiratory Research · 2017 · 215 citations · Full text

Pharmacy, Internal Medicine, Health Assessment +12

Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry

Jürgen Behr, Antje Prasse, Hubert Wirtz et al. · European Respiratory Journal · 2020 · 189 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +16